Event | NASH Summit Europe
October 22, 2019 – October 23, 2019
Kari Wong, Senior Study Director, Metabolon, Inc.
Global Metabolomics: Using global metabolomics in NASH R&D
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome encompassing a spectrum of diseases that range from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. It is the most common liver disease worldwide but, there are no FDA-approved treatments. Complicating the search for treatments, diverse disease drivers including genetics, environmental cues, microbiota metabolism and lifestyle result in an uncertain natural history of NAFLD/NASH. As companies strive for effective therapies, the constellation of putative factors driving NASH has spawned a remarkable array of targets. These programs are further complicated because liver biopsies remain the gold standard for the diagnosis but come with its own set of risks and caveats. A tool for augmenting the challenges of these R&D programs is Metabolon’s Precision Metabolomics™ platform. By identifying over 1000 metabolites in a single sample across diverse pathways that underly NASH pathogenesis, biomarkers and key insights of the target/molecule combination can be illuminated by the platform. This approach can be used at any stage of drug development from target discovery, biomarker identification to the clinic.